An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line

An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line

The rapid evolution of new SARS-CoV-2 variants poses a continuing threat to human health. Vaccination has become the primary therapeutic intervention. The goal of the current work was the construction of immunogenic virus-like particles (VLPs). Here, we describe a human cell line for cost-efficient...

Full description

Bibliographic Details
Main Authors: Stefan Hirschberg, Fatemeh Ghazaani, Ghada Ben Amor, Markus Pydde, Alexander Nagel, Saveria Germani, Lara Monica, Anja Schlör, Hannes Bauer, Jane Hornung, Michael Voetz, Yamen Dwai, Benjamin Scheer, Frauke Ringel, Omar Kamal-Eddin, Christoph Harms, Jonas Füner, Lorenz Adrian, Axel Pruß, Kai Schulze-Forster, Katja Hanack, Julian Kamhieh-Milz
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Vaccines
Subjects:
virus-like particle (VLP)
SARS-CoV-2
vaccine
stable cell line
neutralizing antibodies
Online Access:https://www.mdpi.com/2076-393X/11/9/1469

Internet

https://www.mdpi.com/2076-393X/11/9/1469

Similar Items